Actiflagelin, a new sperm activator isolated from *Walterinnesia aegyptia* venom using phenotypic screening

Tarek Mohamed Abd El-Aziz1,2,3†, Sawsan Al Khoury1,2†, Lucie Jaquillard4, Mathilde Triquigneaux4, Guillaume Martinez5,6, Sandrine Bourgoin-Voillard5,7,8, Michel Sève5,7,8, Christophe Arnoult5,6, Rémy Beroud4 and Michel De Waard1,2,4*

**Abstract**

**Background:** Sperm contains a wealth of cell surface receptors and ion channels that are required for most of its basic functions such as motility and acrosome reaction. Conversely, animal venoms are enriched in bioactive compounds that primarily target those ion channels and cell surface receptors. We hypothesized, therefore, that animal venoms should be rich enough in sperm-modulating compounds for a drug discovery program. Our objective was to demonstrate this fact by using a sperm-based phenotypic screening to identify positive modulators from the venom of *Walterinnesia aegyptia*.

**Methods:** Herein, as proof of concept that venoms contain interesting compounds for sperm physiology, we fractionated *Walterinnesia aegyptia* snake venom by RP-HPLC and screened for bioactive fractions capable of accelerating mouse sperm motility (primary screening). Next, we purified each compound from the positive fraction by cation exchange and identified the bioactive peptide by secondary screening. The peptide sequence was established by Edman sequencing of the reduced/alkylated compound combined to LC-ESI-QTOF MS/MS analyses of reduced/alkylated fragment peptides following trypsin or V8 protease digestion.

**Results:** Using this two-step purification protocol combined to cell phenotypic screening, we identified a new toxin of 7329.38 Da (actiflagelin) that activates sperm motility in vitro from OF1 male mice. Actiflagelin is 63 amino acids in length and contains five disulfide bridges along the proposed pattern of disulfide connectivity C1-C5, C2-C3, C4-C6, C7-C8 and C9-C10. Modeling of its structure suggests that it belongs to the family of three finger toxins with a noticeable homology with bucandin, a peptide from *Bungarus candidus* venom.

**Conclusions:** This report demonstrates the feasibility of identifying profertility compounds that may be of therapeutic potential for infertility cases where motility is an issue.

**Keywords:** Snake venom, *Walterinnesia aegyptia*, Bioactive compounds, Fertility, Sperm motility, Venomics, Tandem mass spectrometry, De novo sequencing, Edman degradation

* Correspondence: michel.dewaard@univ-nantes.fr
† Equal contributors
1 Institute of Thorax, INSERM UMR 1087/CNRS UMR 6291, LabEx Ion Channels, Science and Therapeutics, 8 Quai Moncousu, BP 70721, 44007 Nantes Cedex 1, France
2 University of Nantes, 44007 Nantes, France
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Mammalian fertilization is the result of the successful union of two gametes. Global reports indicate that infertility concerns 15% of all couples worldwide [1]. Infertility is, therefore, becoming a growing concern in modern society. It is estimated that 30% of all infertility cases are due to male factors, namely reduced sperm count, decreased motility (asthenozoospermia) and abnormal morphology. Complete asthenozoospermia (cases of no motility at all) are reported at a frequency of 1 in 5000 men [2, 3].

The molecular pathways and sperm proteins involved in the three main physiological functions of mature sperm that occur in the female tract – sperm motility, capacitation and acrosome reaction – are still the subject of intensive research activities [4, 5]. In spite of possessing a complete understanding of the cascade of events that preside over these sperm functions, it appears clear that subtle interplays between cell surface receptors and ion channels play essential contributing roles to these processes [6–8]. This holds particularly true for sperm motility, which involves a coordinated movement of the flagellum [9–11]. As G-protein coupled receptors (GPCR) and ion channels alone account for the first and second most important targets, as witnessed by currently marketed drugs [12], it would come as no surprise that screening programs with libraries enriched in compounds active on these pharmacological targets should impact these sperm functions.

Herein, we took advantage of our knowledge on animal venoms to develop the proof of concept that bioactive natural peptides may facilitate sperm motility. Ultimately, we hope that some of these compounds have the potential to treat asthenozoospermia. Earlier efforts in using animal venoms to discover compounds that interfere with sperm functions had led to several interesting discoveries. For instance, it was found that snake venoms are rich sources of secreted phospholipase A2 that influences sperm motility, acrosome reaction and in vitro fertilization [13]. This was the case for Oxyuranus scutellatus scutellatus snake venom. Using this lead approach, it also unusually shed light on the importance of mammalian group X phospholipase A2, which is secreted by sperm itself during the acrosome reaction, in positively favoring the outcome of fertilization while concomitantly decreasing sperm motility [14, 15]. More recently, using a venom-targeted screening program, Martinez and collaborators [16] identified spermaurin from Maurus palmatus scorpion venom as a compound improving sperm motility and fertilization in various species. Therefore, there is no doubt that animal venoms should contain many more compounds of interest to modulate spermatic functions in vitro and in vivo.

Among other interesting features of animal venoms as source of compounds, it is worth mentioning the fact that they are intrinsically tailored for in vivo use with very little or no degradation observed upon in vivo administration [17]. Therefore, it is not surprising that many blockbuster therapeutic agents are derived from peptides originally identified in animal venoms. Most evident examples include: captopril, a FDA approved inhibitor of angiotensin-converting enzyme, for hypertension [18]; and epifibatide, an antiplatelet agent isolated from Sistrurus miliarius barbouri venom, which inhibits fibrinogen from binding to platelet glycoprotein IIb/IIIa receptor [19].

With the advent of venomics, a set of proteomic analyses aiming at identifying the compounds present in venoms, drug discovery can be significantly accelerated. These technologies are best backed up with efficient separation techniques such as reversed-phase high performance liquid chromatography (RP-HPLC) – that separates the bioactive compounds based on their hydrophobicity – and ion exchange chromatography – that fractionates them according to their net charge. A two-step separation procedure is generally sufficient to isolate compounds of interest and determine their mass by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) or liquid chromatography electrospray ionization quadrupole time-of-flight mass spectrometry (LC-ESI-QTOF MS) [20] and sequence identity by MS/MS techniques. Besides, Edman degradation remains a method of choice to identify the amino acid sequence of a peptide [21]. During one sequencing run, more than 30 amino acids can be determined in average, although in many cases the N-terminal may be modified or blocked preventing Edman degradation to work. This is the case for 1.5% of spider toxins that possess a N-terminus sequence blocked with pyroglutamate [22].

For the current project, we postulated that we should be able to identify de novo a peptide sequence from a single snake venom active on sperm motility. We reasoned that since so many receptors and channels control sperm motility and that venoms are rich in compounds active on these targets, we should be able to identify a compound without even aiming at diversifying the sources of animal venoms. For proof of concept, we used Waltherinnesia aegyptia black desert cobra venom, a venomous Elapidae snake from desert areas of Africa and Middle East. While its venom is known to cause muscular paralysis and respiratory difficulties in mice, only two neurotoxins have been identified so far: a phospholipase A2 and an acetylcholinesterase [23–26]. While therapeutic potential of this venom has been illustrated by its antitumor efficacy in vitro on human breast carcinoma cell lines [27], it has never been used on human populations to treat infertility issues. For this study on sperm motility, we benefited from the experience built up on the best fractionation techniques to separate the compounds of this venom [28]. Herein, we report on the identification of actiflagelin, a new sperm motility activator using advanced techniques in venomics.
Methods

Materials

The lyophilized venom of a single Egyptian black desert snake *W. aegyptia* (Elapidae) was purchased from Alphabio-toxin Laboratory (Montreuil-au-bois, Belgium). The snake originates from the Sinai Peninsula region of Egypt. Sperm motility M2 medium was purchased from Sigma Aldrich (Saint-Quentin Fallavier, France). Standard count chamber slides (two chambers slides, 100 μm depth) were from Leja Products (Netherlands). The proteolytic enzymes were from Sigma Aldrich (trypsin) and Promega (V8 protease).

RP-HPLC fractionation of the snake venom

The crude venom was fractionated using an analytical RP-HPLC C18 column (XBridge™ BEH 130, 3.5 μm and 4.6 mm ID × 250 mm L column) attached to an Agilent 1260 HPLC (Agilent Technologies). Two mobile phases – A [0.1 trifluoroacetic acid (TFA)/99.9 distilled H₂O (dH₂O) (v/v)] and B [0.1 TFA/90 acetonitrile (ACN)/9.9 dH₂O (v/v/v)] – were used for the RP-HPLC fractionation. Lyophilized snake venom (18 mg) was dissolved in 300 μL of buffer A and filtered before injection into the RP-HPLC system. Elution of venom components was performed at a flow rate of 0.5-2 mL/min with a 5-80% gradient of buffers B/A buffers. Several fractions were collected automatically, lyophilized and stored at −20 °C. For mouse sperm motility assay, RP-HPLC fractions were re-suspended in 100 μL distilled water.

Cation exchange chromatography and desalting of the cation exchange major peaks

The sperm motility assay-positive RP-HPLC fraction was further separated by cation exchange chromatography. The lyophilized RP-HPLC fraction was dissolved in buffer A (20 mM of CH₃COONa, pH 4.5) and injected to a Tosoh Bioscience column (TSK gel SP-STAT, 7 μm, 4.6 mm ID × 10 cm L, Tosoh Bioscience, Germany) coupled to an Agilent 1260 HPLC (Agilent technologies). The elution of fraction components was performed with a linear salt gradient from 0 to 1 M of buffers C/A (buffer C composition: 20 mM CH₃COONa, 1 M NaCl, pH 4.5) over 30 min. Major peaks were collected automatically, lyophilized and stored at −20 °C. For mouse sperm motility assays, the desalted peaks were re-suspended in 100 μL distilled water.

Computer assisted semen analysis (CASA)

All the fractions were tested on mouse sperm solution using computer-assisted semen analysis (CASA) to examine the sperm motility parameters. The two cauda epididymis of 2-4 months-old OF1 male mice (Charles River, France) were isolated by dissection. Spermatozoa from the epididymis were allowed to swim in 1 mL of M2 medium for 10 min at 37 °C. Sperm solution were diluted in M2 medium (ratio 1:50; Sigma-Aldrich) and incubated with RP-HPLC fractions or cation exchange major peak fractions at 37 °C for 10 min (190 μL of sperm solution were mixed with 10 μL of each fraction). After incubation, 25-μL sperm solution was immediately transferred into a standard count chamber slide and kept at 37 °C for microscopic measurement of sperm movement.

Sperm motility parameters were measured using a sperm analyzer (Hamilton Thorn Research, Beverly). The settings employed for analysis were as follows: acquisition rate, 60 Hz; number of frames, 60; minimum contrast, 30; minimum cell size, 4; cell intensity, 75; path velocity, 50; and magnification factor, 0.70. The motility parameters measured were the curvilinear velocity (VCL) and the amplitude of the lateral head displacement (ALH). In addition, we also measured the average path velocity (VAP) and the straight-line velocity (VSL). A minimum of 40 motile spermatozoa were analyzed for each assay. Sperms were their own controls, which explains why two mice were sufficient for this investigation. The comparison between groups of sperms arising from different animals was far less reliable than the protocol described herein.

Amino acid sequence characterization

Sample preparation

All of the screening-positive purified venom peptide obtained after the two chromatography steps was resuspended in 100 mM ammonium bicarbonate (pH 8), reduced with Tris (2-carboxyethyl) phosphine hydrochloride (TECP; incubated at 55 °C for 1 h) and alkylated with iodoacetamide (incubated at room temperature in dark for 1 h) prior to enzyme digestion. The reduced/alkylated venom peptide was digested by using one of the following complementary enzymes: trypsin and V8 protease. The enzyme was added at a 1:20 ratio (enzyme/peptide, w/w) and incubated overnight at 37 °C. The enzymatic digestion was stopped by 0.1% formic acid.

LC-ESI-QTOF MS/MS analysis

A Waters Q-TOF Xevo G2S mass spectrometer equipped with an Acquity UHPLC system and Locksspray source was used for the acquisition of the LC-ESI-QTOF MS and MS/MS data. The digested peptide sample was injected into an Acquity UPLC BEH300 C18 column (1.7 μm, 2.1 mm ID × 150 mm L, Waters). The elution of the peptides was performed with a 10-70% gradient of buffers B/A over 10 min [solvent A composition: dH₂O/formic acid, 99.9/0.1 (v/v) and solvent B composition: ACN/formic acid, 99.9/0.1 (v/v)]. The eluted solution was directly injected into the coupled MS system. Acquisition and
analysis of the peptide samples were carried out in the positive mode, within a mass range of m/z 100-2000 using the Agilent MassLynx software version 4.1 (Waters).

The mass spectrometer settings for the MS analyses were: capillary voltage, 0.5 kV; cone voltage, 40 V; source temperature, 150 °C; desolvation temperature, 600 °C; gas flow, 80 L/h; and gas desolvation, 1000 L/h. MS data were acquired using a data-dependent acquisition method (DDA) for which MS/MS data were acquired using CID activation mode based on mass and charge state of the candidate ions. For calibration, an external lock mass was used with a separate reference spray (LockSpray) using a solution of leucine enkephalin eluted at a flow rate of 5 μL/min. The calibration was based on the MS detection of m/z 278.1141 and 556.2771 ions at collision energy of 23 eV. The resulting MS/MS spectra data were analyzed by de novo sequencing using PEAKS® studio version 5.2 software (Bioinformatics Solutions Inc.) with the following settings: trypsin, or V8 protease; carbamidomethyl (C) as a fixed modification; mass accuracy for MS/MS data at 0.05 Da; and mass accuracy for the precursor mass at 10 ppm. Amino acid sequence scores between 50 and 100 were recorded.

MALDI-TOF MS analysis
The venom fraction 11 was analyzed by MALDI-TOF MS using the 4800 MALDI TOF/TOF Analyzer mass spectrometer (Sciex, France). The 0.5 μL volume sample of the fraction was spotted on the MALDI plate and mixed with 0.5 μL MALDI matrix (CHCA at 10 mg/mL in 70.0% ACN, 29.9% distilled H2O, and 0.1% TFA). The MS spectrum was recorded in positive linear middle mass mode (m/z 2000-20,000, mass tolerance 5 m/z units).

N-terminal sequence determination
Amino acid sequence determination based on Edman degradation was performed using an Applied Biosystems gas-phase sequencer model 492 (s/n: 9510287). Phenylthiohydantoin amino acid derivatives generated at each sequence cycle were identified and quantitated online with an Applied Biosystems Model 140C HPLC system using the data analysis system for protein sequencing from Applied Biosystems (software Procise PC v2.1). The PTH-amino acid standard kit (Perkin-Elmer P/N 4340968) was used and reconstituted according to the manufacturer’s instructions. The procedures and reagents used were as recommended by the manufacturer. Chromatography was used to identify and quantify the derivatized amino acid removed at each sequence cycle. Retention times and integration values of peaks were compared to the chromatographic profile obtained for a standard mixture of derivatized amino acids.

Search of peptides analogues
The highest scoring sequences of the identified peptides were compared to the protein databases (SwissProt, BLASTP 2.6.1+) through the BLAST website (http://blast.ncbi.nlm.nih.gov) for protein similarities. Only proteins from the database with high identity percentages (at least 60%) were selected. The theoretical molecular masses of the identified peptides were calculated online using ExPASy ProtParam website (https://web.expasy.org/protparam).

Structural modelling of actiflagelin
The 3D structure of actiflagelin was modeled using the SwissModel automatic modeling protein software (http://swissmodel.expasy.org).

Results
In an earlier report using W. aegyptia venom, we illustrated that RP-HPLC remains a method of choice for a well-resolved separation of individual compounds [28]. The venom was therefore separated by analytical C18 RP-HPLC and the venom compounds eluted with a gradient of acetonitrile. The eluate was recuperated into fractions according to the chromatogram illustrated in Fig. 1a. As observed, most compounds eluted between fractions 8 and 19 according to the absorbance measured at 214 nm (peptide bond). Hence all these fractions were first lyophilized, re-suspended in 100 μL of dH2O, and 10 μL of each fraction was tested on OF1 male mouse sperm motility using the CASA system as described in the Methods section. A focus was put on curvilinear velocity of the sperm (VCL) which is the most meaningful parameter to investigate when dealing with sperm motility. While fractions 13 and 14, and to a lesser extent fraction 15, stood out as potent inhibitors of sperm motility, only fraction 11 showed promising evidence for sperm motility activation with an average stimulation of 33.41% (Fig. 1b). The VCL value grew up from 106 ± 27 μm/s (n = 68 sperms, mean ± SD) to 141 ± 45 μm/s (n = 74 sperms). Variations that occurred at ±20% were arbitrarily considered of interest, while fractions that had lower modulatory functions were disregarded. Hence, fraction 11 was analyzed by MALDI-TOF MS in the linear mode and led to the detection of five ions with m/z values ranging between m/z 6389.9 and m/z 7605.9 (Fig. 1c).

To identify which compound of fraction 11 is responsible for the sperm motility activation, fraction 11 compounds were further individually purified by cation exchange chromatography (Fig. 2a). As illustrated by the chromatogram, five compounds eluted along the NaCl concentration gradient and out of primary fraction 11. Assuming closely related molecular masses for the compounds of fraction 11, which seems to be the case (see Fig. 1c), it appears that compounds 1, 3 and 5 are present in greatest abundance in fraction 11 according to the absorbance values at 214 nm.
In contrast, compounds 2 and 4 stand out as the least abundant ones within this fraction.

After desalting, each one of these five compounds were tested on the sperm VCL parameter at a concentration that should closely mimic the initial concentration within the RP-HPLC fraction 11 if one takes into account a recovery of about 80% from this fraction following cation exchange. This recovery was assessed using reference compounds (not shown). Compound 3 turned out to be a positive modulator of VCL.

![Fig. 1 Bioactivity of W. aegyptia venom primary fractions on OF1 mouse sperm motility.](image)
Fig. 2 (See legend on next page.)
In this batch of OF1 mouse sperm, the VCL value increased from an average 202 ± 85 mm/s (n = 43 sperms) to 257 ± 73 mm/s (n = 45 sperms), which represents an average increase of 27.2%. This increase matches the increase in VCL induced by RP-HPLC fraction 11 itself indicating that cation exchange peak N° 3 largely recapitulates the effect of the full fraction 11. As shown by analytical C18 RP-HPLC, the peptide has been purified to homogeneity (Fig. 2b).

LC-ESI-QTOF MS analysis illustrates several charge states of the compound (4+ to 8+) (Fig. 2c) leading to an experimental molecular mass of 7329.71 Da, which is very closely related to one of the components detected in RP-HPLC fraction 11 that had a molecular mass of 7329.8 Da as detected by MALDI-TOF MS (Fig. 1c). This compound was termed actiflagelin in reference to its activation potential of sperm motility, which should be related to flagellum function. Besides compound 3, compound 1 was also active on sperm motility and will be characterized and treated in a separate report (data not shown). This approach does however illustrate that this fraction 11 contained two compounds that both acted positively on sperm motility.

The most logical follow-up step was de novo sequencing of actiflagelin. As a first step, actiflagelin was reduced using TCEP for 1 h at 55 °C and alkylated with iodoacetamide for 1 h at room temperature and in the dark. The alterations in molecular mass (from 7329.707 Da to 7899.907 Da), taking into account the reduction of disulfide bridges and the addition of 57.02 Da upon alkylation, illustrates that actiflagelin should contain ten cysteine residues. In addition, the differences in molecular masses would also suggest that all these cysteine residues engage in five disulfide bridges (Fig. 3a).

Samples of the reduced/alkylated actiflagelin were then digested overnight at 37 °C with either trypsin (w/w trypsin/actiflagelin with a ratio of 1/20) or V8 protease (w/w V8 protease/actiflagelin ratio of 1/20). All digested fragments were purified by ZipTipC18 and first analyzed by LC-ESI-QTOF MS. Trypsin generated eight overlapping sequences, purified actiflagelin peptide fragments from V8 protease digestion were sequenced by Edman degradation, which yielded additional four peptide sequences, this time covering the central region of actiflagelin and providing most of the C-terminus of this toxin (Fig. 4a). The Edman degradation peptides unambiguously identified Leu residues at positions 13, 37 and 60, while it identified Ile residues at positions 15 and 31. The presence of ten Cys residues (Fig. 4b) is coherent with the conclusion drawn that there should be five disulfide bridges within actiflagelin upon mass shift observed with the full reduction and alkylation of the peptide (Fig. 3a).

All ions were analyzed by LC/ESI QTOF MS/MS and de novo sequencing software (PEAKS® studio version 5.2 software) used to define the amino acid sequence of each actiflagelin fragment. An example of de novo sequencing by LC-ESI-QTOF MS/MS is provided in Fig. 3c for the m/z 755.8411 [+2] ion. The resulting sequence of 12 amino acids was RW(L/I)GCAKTCTEE. A total of three peptides could be sequenced using this method following reduction, alkylation and V8 protease digestion (see colored peptide fragments in Fig. 4a). Peak scores for these peptides were 88, 99 and 91% from N- to C-terminus, respectively. At this stage, Ile or Leu residues can be resolved by LC-ESI-QTOF MS/MS and are thus described as (L/I).

Similarly, seven peptides could be sequenced after trypsin digestion of reduced/alkylated actiflagelin (Fig. 4a). While the use of both proteases allowed for the identification of overlapping sequences, thus permitting the reconstruction of most of the full-length sequences, there remained uncertainties about the central sequence and the extreme C-terminus of actiflagelin. In addition, we could not define whether we had Leu or Ile residues at defined locations within the primary structure since LC-ESI-QTOF MS/MS based on CID activation mode does not discriminate between these two entities. To solve these issues, purified actiflagelin peptide fragments from V8 protease digestion were sequenced by Edman degradation, which yielded additional four peptide sequences, this time covering the central region of actiflagelin and providing most of the C-terminus of this toxin (Fig. 4a). The Edman degradation peptides unambiguously identified Leu residues at positions 13, 37 and 60, while it identified Ile residues at positions 15 and 31. The presence of ten Cys residues (Fig. 4b) is coherent with the conclusion drawn that there should be five disulfide bridges within actiflagelin upon mass shift observed with the full reduction and alkylation of the peptide (Fig. 3a).

The partially reconstructed sequence has a theoretical molecular mass of 7233.22 Da assuming that the five disulfide bridges are connected and that the peptide is not amidated at the C-terminus. Thus, there is still a missing molecular mass gap of 96.48 Da that is compatible with a C-terminal Pro residue at the end of actiflagelin (115.13 Da – 18 Da of H2O when engaged in peptide bond = 97.13 Da). If, in addition, the peptide is amidated (~1 Da), then Pro would perfectly match the missing residue in the sequence to provide the correct missing mass. This, in turn, would reach a theoretical mass of 7233.22 Da.
actiflagelin that matches the observed experimental mass of our sperm motility activator.

Finally, we performed a Blast search using the almost fully reconstructed sequence of actiflagelin, which yielded a match with several animal toxins (Fig. 4b). Sequence identity with these matches ranged between 65% for toxin S6C6 and 86% for bucandin. The sequence of actiflagelin was deposited in the UniProt database (http://www.uniprot.org/help/submissions) with a SPIN ID number of SPIN200010115. The proposed disulfide bridge pattern of actiflagelin is provided in Fig. 4c based on its sequence similarity with bucandin. Finally, a 3D model of actiflagelin built by the SwissModel automatic modeling protein software is shown and illustrates that actiflagelin is a three-finger toxin (Fig. 4d).

Discussion

Herein, we demonstrate the value of phenotypic screening on an exotic cell type (mouse sperm) that is not predicted to be a normal venom target in toxinology. We followed a two-step purification procedure using RP-HPLC as first step fractionation and cation-exchange for the final purification of the compounds of interest. We based our assay on two simple reasoning schemes: (i) sperm contains diverse and high levels of cell surface receptors and ion channels [13, 29, 30], and (ii) any animal venom is known to contain compounds that efficiently target these two classes of cell surface receptors [31–35]. Hence, it is logic that by taking randomly any kind of animal venom and by screening for compounds that would alter sperm motility, a process governed to a large extent by ion channels and other types of cell surface receptors, we should detect interesting compounds with modulatory function.

By following our purification scheme, we identified one activating primary fraction (11) and two inhibitory ones (fractions 13 and 14) demonstrating the richness in sperm-modulating compounds that should be present in W. aegyptia venom. The
inhibitory fractions will remain interesting lead fractions for the discovery of at least two additional compounds that possess contraceptive potential. Globally, this observation further assures that animal venoms comprise rich libraries for the discovery of sperm-modulating compounds.

With regard to the inhibitory fraction 11, it was of interest to determine whether the activity was linked to a single compound, several compounds possessing a similar inhibitory activity or to a synergistic effect of several compounds that, if tested apart, would lack efficiency. Upon purification by cation-exchange chromatography, we found out that at least two compounds activate sperm motility within the single RP-HPLC fraction 11, thereby validating the second hypothesis. Time will tell whether the second compound is of the same family of actiflagelin or whether it significantly differs in sequence and cell receptor. All that can be stated at this level is that this second compound should have a molecular mass that resembles the one of actiflagelin according to MALDI TOF MS analysis.

Snake peptides in the range of 6-7 kDa are notoriously active on GPCR [36, 37]. Defining the molecular target of actiflagelin would be beneficial. It would most likely lead to the identification of a GPCR type that could represent a novel lead target for new screening campaign using this time libraries of small chemical compounds that should be easier to synthesize, more cost-effective, and allow oral intake for the control of sperm motility in infertile men. Such a strategy will require: the successful chemical synthesis of actiflagelin; and the identification of actiflagelin receptors by reverse pharmacology, i.e., by using synthetic actiflagelin as a bait in affinity columns. For the time being, actiflagelin will be useful to assess at a later stage its ability to improve the fertilization outcome in vitro. In addition, chemical synthesis of tagged versions of actiflagelin will help examining the cell surface distribution of its receptor and its relevance to sperm motility problems.

**Conclusions**

We demonstrate the power of proteomics for de novo identification of venom components that have been identified through a process of phenotypic screening. This method is applicable for any cell type, function or pathology in which cell surface receptors – such as GPCR or ion channels – are suspected to play an important role.
Acknowledgments
We acknowledge the technical expertise of all Smartox team members.

Funding
We acknowledge financial support from the Egyptian government for a joint supervision scholarship to Tarek El-Ad El Aziz. We thank Smartox Biotechnology for financial support and its staff for providing technical assistance to venom fractionation and LC-ESI-QTOF-MS analyses. We thank INSERM for financial support to Michel De Waard. This program is supported by a grant from the Agence Nationale de la Recherche to the LabEx Ion Channels, Science and Therapeutics under the code number ANR-11-LABX-0015.

Authors’ contributions
TMAEA and SAR contributed equally to this work. TMAEA, SAK, and GM performed toxin screening experiments and sperm motility assays. TMAEA, LI, MT, and SBV did MS analyses. MS, CA, RB, and MDW did experimental supervision. MDW wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All animal procedures were run according to the French guidelines on the use of animals in scientific investigations with the approval of the local ethical committee (Grenoble-Institut des Neurosciences – Ethics Committee, study agreement number 004). Mice were euthanized by cervical dislocation. No human samples were used.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Institute of Thorax, INSERM UMR 1087/CNRS UMR 6291, LabEx Ion Channels, Science and Therapeutics, 8 Quai Moncousu, BP 70721, 44007 Nantes Cedex 1, France. 2University of Nantes, 44007 Nantes, France. 3Zooology Department, Faculty of Science, Minia University, El-Minia 61519, Egypt. 4Smartox Biotechnology, 570 Rue de la Chimie, 38400 Saint Martin d’Hères, France. 5University Grenoble Alpes, PROMETHEE proteomic Platform, 38000 Grenoble, France. 6INSERM 1209, CNRS UMR 5309, Equipe “Génétique, Epigénétique et Thérapies de l’Infertilité”, 38000 Grenoble, France. 7Institut de Biologie et de Pathologie, CHU de Grenoble, PROMETHEE proteomic Platform, 38000 Grenoble, France. 8Inssem U1055, LBFA and BEEGy, Saint Martin d’Hères, France.

Received: 18 July 2017 Accepted: 2 January 2018
Published online: 23 January 2018

References
1. Thonneau P, Marchand S, Tallec A, Ferial ML, Ducot B, Lansac J, et al. Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988-1989). Hum Reprod. 1991;6(6):811–6.
2. Otteca C, Vehreyen G, Raick D, Camus M, Devroey P, Tournaye H. Absolute asthenozoospermia and ICSI: what are the options? Hum Reprod Update. 2011;17(5):684–92.
3. Curi SM, Ariagno JJ, Chenlo PH, Mendeluk GR, Pugliese MN, Sardi Segovia LM, et al. Asthenozoospermia: analysis of a large population. Arch Androl. 2003;49(5):343–9.
4. Salicioni AM, Platt MD, Wertheimer EV, Arcelay E, Allaire A, Sosnik J, et al. Signalling pathways involved in sperm capacitation. Soc Reprod Fertil Suppl. 2007;65:245–59.
5. Jungnickel MK, Sutton KA, Florman HM. In the beginning: lessons from fertilization in mice and worms. Cell. 2003;114(4):401–4.
6. Lishko PV, Kirichok Y, Ren D, Navarro B, Chung JJ, Clapham DE. The control of male fertility by spermatozoan ion channels. Annu Rev Physiol. 2012;74:453–75.
7. Danzor A, Nishigaki T, Beltran C, Treviño CL. Calcium channels in the development, maturation, and function of spermatozoa. Physiol Rev. 2011; 91(4):1305–55.
8. Zhang D, Gopalakrishnan M. Sperm ion channels: molecular targets for the next generation of contraceptive medicines? J Androl. 2005;26(6):643–53.
9. Wiesner B, Weiner J, Middendorff R, Hagen V, Kaupp UB, Weyand I. Cyclic nucleotide-gated channels on the flagellum control cAMP entry into sperm. J Cell Biol. 1998;142(2):473–84.
10. Hirsch KD, de Pinto V, Aires VA, Schneider X, Messina A, Hirsch E. Voltage-dependent anion-selective channels VOCA2 and VOCA3 are abundant proteins in bovine outer dense fibers, a cytoskeletal component of the sperm flagellum. J Biol Chem. 2004;279(15):15281–8.
11. Lishko PV, Botchkina IL, Fedorenko A, Kirichok Y. Acid extrusion from human spermatozoa is mediated by flagellar voltage-gated proton channel. Cell. 2010;140(3):327–37.
12. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5(12):943–6.
13. Escoffier J, Couvet M, de Pomyers H, Ray PF, Sève M, Lambeau G, et al. Snake venoms as a source of compounds modulating sperm physiology: secreted phospholipases A2 from Oxyuranus scutellatus scutellatus impact sperm motility, acrosome reaction and in vitro fertilization in mice. Biochimie. 2010;92(7):826–36.
14. Escoffier J, Jénel I, Tanemoto A, Takeomi Y, Payne C, Coatrieux C, et al. Group X phospholipase A2 is released during sperm acrosome reaction and controls fertility outcome in mice. J Clin Invest. 2010;120(5):1415–28.
15. Escoffier J, Pierre VJ, Jénel I, Munch L, Boudhraa Z, Ray PF, et al. Group X secreted phospholipase A2 specifically decreases sperm motility in mice. J Cell Physiol. 2011;226(10):2601–9.
16. Martínez G, Hograindleur JP, Voin V, Sbihi S, Abi Nahed R, Abd El Aziz TM, Escoffier J, et al. Sperm motility and human fertility. Exp Clin Cardiol. 2008;13(4):192–9.
17. Perret P, Ahmadi M, Riou L, Bacot S, Pecher J, Pollicot C, et al. Biostimulation, stability, and blood distribution of the cell penetrating peptide (CPP) present in the venom of Bothrops jararacussu. Br J Pharmacol Chemother. 1965;24(1):163–9.
18. Hahmouzadeh M, Furukawa M, Goldsberry S, Movahed MR. Chemical structures and mode of action of intravenous glycoprotein IIB/IIa receptor blockers: a review. Exp Clin Cardiol. 2008;13(4):192–7.
19. Finehout EJ, Lee KH. An introduction to mass spectrometry applications in biological research. Biochem Mol Biol Educ. 2004;32(2):93–100.
20. Edman P. A method for the determination of amino acid sequence in peptides. Arch Biochem. 1949;22(3):475.
21. Wood DL, Mijlenovic T, Cai S, Raven RJ, Kaas Q, Escubas P, et al. ArachnoServer: a database of protein toxins from spiders. BMC Genomics. 2009;10:375.
22. Gitter S, Moroz-Perlmutter C, Boss JH, Livni E, Rechnic J, Goldblum N, et al. Studies on the snake venoms of the near east: Walterinnesia aegyptia and Pseudocerastes fieldii and their effects on normal lymphocytes through PI3K/AKT, NFκB and ERK signaling. Lipids Health Dis. 2012;11:27.
28. Abd El Aziz TM, Bourgoin-Voillard S, Combernale S, Beroud R, Fadl M, Seve M, et al. Fractionation and proteomic analysis of the Walterinnesia aegyptia snake venom using OFFGEL and MALDI-TOF-MS techniques. Electrophoresis. 2015;36(20):2594–605.

29. Darszon A, Acevedo JJ, Galindo BE, Hernández-González EO, Nishigaki T, Treviño CL, et al. Sperm channel diversity and functional multiplicity. Reproduction. 2006;131(6):977–88.

30. Shukla KK, Mahdi AA, Rajender S. Ion channels in sperm physiology and male fertility and infertility. J Androl. 2012;33(5):777–88.

31. Suzuki N, Yamazaki Y, Brown RI, Fujimoto Z, Morita T, Mizuno H. Structures of pseudechetoxin and pseudecin, two snake-venom cysteine-rich secretory proteins that target cyclic nucleotide-gated ion channels: implications for movement of the C-terminal cysteine-rich domain. Acta Crystallogr D Biol Crystallogr. 2008;64(Pt 10):1034–42.

32. Diochot S, Baron A, Salinas M, Douguet D, Scarzello S, Dabert-Gay AS, et al. Black mamba venom peptides target acid-sensing ion channels to abolish pain. Nature. 2012;490(7421):552–5.

33. Serafim FG, Reali M, Cruz-Höfling MA, Fontana MD. Action of Micrurus dumerilii carinicauda Coral snake venom on the mammalian neuromuscular junction. Toxicon. 2002;40(2):167–74.

34. Siew JP, Khan AM, Tan PT, Koh JL, Seah SH, Koo CY, et al. Systematic analysis of snake neurotoxins’ functional classification using a data warehousing approach. Bioinformatics. 2004;20(18):3466–80.

35. Carbajal-Saucedo A, López-Vera E, Bénard-Valle M, Smith EN, Zamudio F, de Roodt AR, et al. Isolation, characterization, cloning and expression of an alpha-neurotoxin from the venom of the Mexican coral snake Micrurus lacteolus (Squamata: Elapidae). Toxicon. 2013;66:64–74.

36. Maiga A, Mourier G, Quinton C, Gales C, Denis C, Lluel P, et al. G protein-coupled receptors, an unexploited animal toxin targets: exploration of green mamba venom for novel drug candidates active against adrenoceptors. Toxicon. 2012;59(4):487–96.

37. Rouget C, Quinton L, Maiga A, Gales C, Masuyer G, Malosse C, et al. Identification of a novel snake peptide toxin displaying high affinity and antagonist behaviour for the alpha2-adrenoceptors. Br J Pharmacol. 2010;161(6):1361–74.